Pathstone Family Office’s Exact Sciences EXAS Stock Holding History

Pathstone Family Office’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$347K	Buy	5,088 +1,067	+27%	+$90.5K	﹤0.01%	1222
2023 Q2	$387K	Sell	4,021 -164	-4%	-$12.8K	0.01%	861
2023 Q1	$288K	Sell	4,185 -6,545	-61%	-$421K	﹤0.01%	928
2022 Q4	$513K	Buy	+10,730	New	+$438K	﹤0.01%	1087
2022 Q1	–	Sell	-2,654	Closed	-$206K	–	989
2021 Q4	$206K	Sell	2,654 -383	-13%	-$33.8K	0.01%	833
2021 Q3	$290K	Buy	3,037 +698	+30%	+$73.7K	0.01%	688
2021 Q2	$291K	Buy	2,339 +682	+41%	+$81.4K	0.01%	659
2021 Q1	$218K	Buy	+1,657	New	+$227K	0.01%	587
2020 Q3	–	Sell	-51	Closed	-$4K	–	861
2020 Q2	$4K	Hold	51	–	–	﹤0.01%	580
2020 Q1	$3K	Buy	+51	New	+$4.14K	﹤0.01%	658
2019 Q4	–	Sell	-51	Closed	-$5K	–	492
2019 Q3	$5K	Buy	+51	New	+$5.81K	﹤0.01%	536
2014 Q4	–	Sell	-101	Closed	-$2K	–	163
2014 Q3	$2K	Buy	+101	New	+$1.85K	0.01%	289
2014 Q2	–	Sell	-100	Closed	-$1K	–	145
2014 Q1	$1K	Buy	+100	New	+$1.35K	﹤0.01%	171
2013 Q4	–	Sell	-1,071	Closed	-$13K	–	253
2013 Q3	$13K	Buy	+1,071	New	+$13.7K	0.06%	162

Other funds holding EXAS

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pathstone Family Office's EXAS Position: Q3 2023 in Review

Pathstone Family Office increased its Exact Sciences (EXAS) stake by 27% in Q3 2023, buying an estimated $90.5K and bringing the position to 5,088 shares worth $347K. The position accounts for ﹤0.01% of the portfolio, ranked #1222.

Pathstone Family Office first reported a position in EXAS in Q3 2013 and has held it in 14 quarters since. The position peaked at $513K in Q4 2022. 624 funds tracked by Wall St. Rank hold EXAS as of Q3 2023.

Pathstone Family Office held 5,088 shares of Exact Sciences worth $347K as of Q3 2023.
Pathstone Family Office bought 1,067 Exact Sciences shares in Q3 2023, an estimated $90.5K.
Exact Sciences made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1222 holding.
Pathstone Family Office first reported a position in Exact Sciences in Q3 2013 and has held it in 14 quarters since.
Pathstone Family Office's Exact Sciences position peaked at $513K in Q4 2022.
624 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.